[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340 ; 341-360 ; 361-380

NICE TAs 301-320

 REF

TITLE

DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)

       
 TA301

 Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271) (TA301)

11.8.2 Ocular diagnostic and peri-operative preparations  

 

  TA302

 Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)

Not recommended by NICE

 

  TA303

 Teriflunomide for treating relapsing-remitting multiple sclerosis (TA303)

8.2.4 Other Immunomodulating Drugs 

 

 TA304

 Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (TA304)

 Not pharmacy

 
 TA305

 Aflibercept for treating visual impairment caused by macular oedema  secondary central retinal vein occlusion (TA305) 

11.8 Miscellaneous ophthalmic preparations

 
 TA306

 Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma (TA306)

   DHFT protocol
 TA307

Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

Not recommended by NICE

 EMCN algorithm
 TA308

Rituximab in combination with glucocorticoids for treating antineutrophil cytoplasmic antibody-associated vasculitis (TA308)

8.2.3 Rituximab & Alemtuzumab

 
 TA309

Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (TA309)

Not recommended by NICE

 EMCN algorithm
 TA310

Afatinib for treating epidermal growth factor receptor mutationpositive locally advanced or metastatic non-small-cell lung cancer (TA310)

 

 EMCN algorithm
 TA311

Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

   DHFT protocol
 TA312

Alemtuzumab as an option for treating adults with active relapsing–remitting multiple sclerosis (TA312)

8.2 Drugs affecting the immune respons

 
 TA313

Ustekinumab for treating active psoriatic arthritis (TA313)

Not recommended by NICE

 
 TA314

Implantable cardioverter defibrillators (TA314)

No drug implications

 
 TA315

Canagliflozin is recommended as an option for treating type 2 diabetes (TA315)

    6.1.2.3 Other anti-diabetics  
 TA316

Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316)

   EMCN algorithm
 TA317

Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

 2.9 Antiplatelet drugs

 
 TA318

Lubiprostone for treating chronic idiopathic constipation (TA318)

 1.6 Laxatives

 
 TA319

Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

   EMCN algorithm
 TA320

Dimethyl fumarate for active-relapsing multiple sclerosis (TA320)

8.2.4 Other Immunomodulating Drugs